Brussels, 10th November 2015

Auditorium Dupréel

ULB, Solbosch campus, 44 avenue Jeanne, 1050 Brussels


8h45: Registration & welcome coffee

9h30: Welcome

Didier VIVIERS, Rector of ULB

Marco SCHETGEN, Dean of the Faculty of Medicine

Bruno VAN POTTELSBERGHE, Dean of Solvay Brussels School of Economics and Management

Michel GOLDMAN, Founder of the Institute for Interdisciplinary Innovation in healthcare (I3h)

Morning session: “Innovation for health”

Chairs: Eric DE KEULENEER, Chairman of the Board, ULB & Peter O’DONNELL, Associate Editor, Politico

10h00 – 10h20

Richard BERGSTROM, Director General, European Federation of Pharmaceutical Industries and Associations
Innovation for health: the commitment of the biopharmaceutical industry”
10h20 – 10h40 Sergio BONINI, Adviser, European Medecine Agency

“Innovation from a regulatory perspective”

10h40 – 11h10 Coffee break
11h10 – 11h30 Sander van DEVENTER, Managing Partner at Forbion Biocapital & Professor at Leiden University Medical Center
“Financial incentives to boost innovation: what is needed?”
11h30 – 11h50 Jean-Louis VINCENT, President, World Federation of Societies of Intensive and Critical Care Medicine & Professor at ULB
“Clinical trials: who is responsible for what ?”
11h50 – 12h10 Bettina RYLL, Founder, Melanoma Patient Network
“A societal perspective: Time for changes !”
12h10 – 13h00 Patient-centric innovation: what does it mean ?”

Round table introduced by Mary BAKER, President Year Of the Brain 2015, European Brain Council

13h00 – 14h00 Walking lunch

Afternoon session: “Anti-TNF therapy, a paradigm for biopharmaceutical innovation”

Chairs:  Michel GOLDMAN, I³h Founder & Sander van DEVENTER, Forbion Biocapital and Leiden University

14h00 – 14h30 Bruce BEUTLER, Nobel Prize Laureate in Medicine 2011, University of Texas Southwestern Medical Center, USA
“The discovery of new targets for inflammatory disorders”
14h30 – 15h00 Sir Marc FELDMANN, Laureate of Albert Lasker Award 2003, Kennedy Institute of Rheumatology, University of Oxford, UK
“Pioneering anti-TNF therapy: lessons learned point path to future progress?”
15h00 – 15h30 Paul RUTGEERTS, Emeritus Professor of Medicine, KU Leuven
“Targeting cytokines in inflammatory bowel disease: clinical research at the forefront”
15h30 – 16h00 Roch DOLIVEUX,  Chairman of the Board at Vlerick Business School, retired CEO of UCB, and past-Chair of the IMI Governing Board
“Bringing new biologicals to patients: the mission of the research-based pharmaceutical industry”
16h00 – 16h30 Coffee break
16h30 – 17h30  What did we learn from the anti-TNF journey ?”

Round table introduced by Sander van DEVENTER & Mathias EVERS, Director, McKinsey

17h30 Cocktail-reception

With the kind support of :

M&S  Capture d’écran 2015-10-30 à 11.00.45         Janssen        Capture d’écran 2015-11-02 à 10.45.35

EFPIA_Logo_Def  LOGO SANOFITeva english logo whiteLOGO EEBIC          LOGO_fr

                                                                      logo BI     logo pfizer_rgb_pos      RVB de base